UT Health San Antonio, the academic health center of The University of Texas at San Antonio (UT San Antonio) is launching a multi-phase clinical study to better understand how the drug rapamycin may promote healthy aging. Funded by the National Institute on Aging, the study will examine dosing, safety and long-term effects to help guide future research on extending health span.
UT San Antonio researchers Ellen Kraig, PhD, professor in the Department of Cell Systems and Anatomy, Dean Kellogg Jr., MD, PhD, professor in the Department of Medicine, Division of Geriatrics, Gerontology and Palliative Medicine, and Brett Ginsburg, PhD, professor in the Department of Psychiatry and Behavioral Sciences in the Joe R. and Teresa Lozano Long School of Medicine, are leading the study.
Rapamycin is widely…